4D Molecular Therapeutics’ (FDMT) “Sell (D-)” Rating Reaffirmed at Weiss Ratings
Weiss Ratings reissued their sell (d-) rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT – Free Report) in a report released on Wednesday morning,Weiss Ratings reports. Several other equities research analysts have also recently issued reports on FDMT. Chardan Capital reduced their target price on 4D Molecular Therapeutics from $28.00 to $25.00 and set a […]
Weiss Ratings reissued their sell (d-) rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT – Free Report) in a report released on Wednesday morning,Weiss Ratings reports. Several other equities research analysts have also recently issued reports on FDMT. Chardan Capital reduced their target price on 4D Molecular Therapeutics from $28.00 to $25.00 and set a […]
